Fulvestrant can inhibit ER-related biological process, but concomitantly activate GPER1, which in turn transactivated EGFR causing cell proliferation, invasion and migration, which were demonstrated in breast, endometrial, ovarian, and recently in lung cancers (27). This evidence concerns the gene EGFR and lung carcinoma.